相关实验视频

Updated: May 24, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

BKT300:一种新的抗白血病小分子,准细胞动力学1 (PRC1) 途径的蛋白调节器

Amnon Peled¹, Michal Abraham², Hanna Wald¹

¹Hadassah University Hospital.

Research square

|March 4, 2025

概括

细胞动化1 (PRC1) 的蛋白调节剂在急性髓性白血病 (AML) 中过度表达. 新型抑制剂BKT300针对PRC1,在临床前模型中有效降低AML细胞活力和瘤生长.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

细胞动化1 (PRC1) 的蛋白调节器在癌症中经常过度表达,与预后不佳相关.
PRC1在细胞分裂和细胞骨组织中发挥作用,使其成为潜在的治疗点.

研究的目的:

研究PRC1在急性髓性白血病 (AML) 中的作用.
在AML模型中评估小分子PRC1抑制剂BKT300的疗效.

主要方法:

在AML患者和细胞系中评估PRC1表达.
利用体外测试来确定BKT300对AML细胞周期,细胞亡和细胞骨动态的影响.
在老鼠异种移植AML模型中评估了BKT300对瘤生长和血液形成的影响.

主要成果:

在AML中,PRC1过度表达,较高水平与患者存活时间减少有关.
BKT300直接抑制PRC1,导致细胞循环停止,细胞亡以及AML细胞中actin/microtubule形成的破坏.
在小鼠模型中,BKT300表现出显著的瘤生长抑制 (98%) 和回归 (89.4%),对正常血液形成没有不良影响.

结论:

在AML中,PRC1是相关的治疗点.
BKT300显示显著的临床前有效性和安全性作为AML的向治疗.
BKT300代表了一个有前途的第一类治疗选择,用于高级AML.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Positive Regulator Molecules

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...